Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Rapamycin is a prescription mTOR inhibitor (originally an anti-rejection immunosuppressant) used off-label in the longevity community for its lifespan-extending effects in animals. It is the opposite of an anabolic: by inhibiting mTORC1 it can actually oppose muscle protein synthesis. It does not raise testosterone, IGF-1, or muscle mass and confers no athletic advantage, if anything it restrains the growth signalling lifters try to maximise. Rated 1 on the natty scale as a longevity/healthspan drug with no muscle-building or performance-enhancing effect.
Overview
The most reproducibly life-extending pharmaceutical in mammals and the flagship of the longevity-drug community. Rapamycin is an mTOR inhibitor: at the low, intermittent (typically weekly) doses used for healthspan it is intended to inhibit mTORC1, a nutrient/growth sensor, to trigger autophagy and mimic aspects of caloric restriction, while sparing mTORC2. This is a fundamentally different use case from the daily immunosuppressive dosing it is FDA-approved for. Its most important practical caveat for lifters is that the very pathway it inhibits (mTOR) is the master switch for muscle protein synthesis, a real tension when the goal is muscle.
Purpose & Use Cases
Longevity / Healthspan
The strongest small-molecule lifespan-extension data in mammals. The NIA Interventions Testing Program extended median lifespan in genetically heterogeneous mice across independent sites, even when started in late life. Human healthspan data are early and mixed.
Autophagy Induction
By releasing mTORC1's brake on autophagy, rapamycin promotes clearance of damaged proteins/organelles, the mechanistic rationale behind most longevity interest.
Immune Modulation
At high daily doses it is immunosuppressive (its approved use). Paradoxically, low intermittent dosing of rapalogs improved vaccine response and immune function in older adults in some studies, a dose- and schedule-dependent effect.
Benefits
- Best-replicated pharmacological lifespan extension in mammals (rodent data)
- Induces autophagy: a hallmark-of-aging pathway
- Weekly dosing convenience (long half-life)
- Non-hormonal: does not suppress the HPTA
- Emerging human trials on muscle/strength and healthspan endpoints
Good to Know
mTOR inhibition vs. muscle: a real tension (the "brake on gains")
mTORC1 is the master switch for muscle protein synthesis. It is exactly the pathway that resistance training and anabolics ramp up. Rapamycin inhibits it. So on paper, chronically blunting mTOR opposes hypertrophy: a single dose of rapamycin can blunt the acute rise in muscle protein synthesis after training. This is analogous to the antioxidant-vs-hypertrophy tradeoff with resveratrol, a longevity tool that can conflict with maximal growth. If your primary goal this block is building muscle, that conflict is worth taking seriously.
But the nuance: intermittent dosing MIGHT spare hypertrophy. Mouse data say maybe, the human trial is not reassuring
The tension is real yet unsettled, and dose/schedule matters. In a 2025 mouse study (bioRxiv preprint, not yet peer-reviewed), progressive weighted-wheel training produced similar myofiber hypertrophy, grip strength, and running-capacity gains whether mice got frequent (3x/week) or intermittent (1x/week) rapamycin; both schedules caused some post-training glucose intolerance, but it was milder with intermittent dosing (it reduced, not eliminated, the metabolic disruption seen with frequent dosing). The completed human trial cuts the other way: RAPA-EX-01, a randomized double-blind placebo-controlled trial, gave 65-85-year-olds once-weekly 6mg sirolimus alongside a 13-week home exercise program and (published April 2026 in the Journal of Cachexia, Sarcopenia and Muscle) found sirolimus did NOT enhance and, in sensitivity analyses, may have modestly attenuated the functional gains: on the primary 30-second chair-stand test the placebo group outperformed sirolimus by ~2.1 reps in the intention-to-treat analysis (not statistically significant, p=0.089), but the gap reached significance in the complete-case (p=0.045) and per-protocol (p=0.007) analyses. Adverse events were also more frequent on sirolimus (99 vs 63 events across the trial, including one possibly drug-related serious event). Honest read: frequent/daily mTOR inhibition clearly opposes anabolism; low weekly "pulse" dosing MIGHT leave more room for mTOR (and muscle) to rebound between doses in animals, but the one human trial leans neutral-to-negative rather than reassuring. Not a green light for a dedicated mass phase.
Longevity dosing is NOT immunosuppressive dosing
The FDA-approved use is daily 2-5mg to suppress the immune system after organ transplant. The longevity use is ~1-6mg ONCE WEEKLY. The schedule is the whole point: intermittent low dosing is intended to inhibit mTORC1 (autophagy, healthspan) while sparing mTORC2 and avoiding the immunosuppression/glucose/lipid problems of chronic dosing. Conflating the two dosing worlds is the most common mistake.
Immunosuppression caveat is still real
Even at weekly doses, rapamycin is an immunosuppressant by class. Most longevity users report few issues and some data suggest low-dose rapalogs can improve immune/vaccine responses in the elderly, but caution around active infection, live vaccines, and surgery/wound healing is warranted, and it should be physician-supervised.
Human longevity evidence is early and modest
The rodent lifespan data are the strongest for any drug, but they do not automatically transfer. The PEARL trial (published 2025 in Aging, 48 weeks, 5mg or 10mg compounded rapamycin once weekly vs. placebo in healthy adults) found the intervention was safe and well tolerated but did not move its primary endpoint (visceral adipose tissue was unchanged); lean mass rose in women on the 10mg arm and a few other secondary/quality-of-life measures improved. Note the compounded rapamycin used tested at roughly one-third the blood concentration of commercial tablets at 24h, so the "5-10mg" doses were pharmacologically milder than the same numbers would be with Rapamune. Treat rapamycin as a promising, mechanistically grounded longevity bet, not a proven anti-aging cure in humans.
Grapefruit / CYP3A4 matters
Rapamycin is a CYP3A4 and P-glycoprotein substrate. Grapefruit and CYP3A4 inhibitors raise its levels; CYP3A4 inducers lower them. Keep intake and timing consistent and review concurrent medications with a physician.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 2 – 3 mg/week |
| Intermediate | 3 – 6 mg/week |
| Advanced | 6 – 10 mg/week |
Community/off-label longevity dosing is roughly 1-6mg once weekly (some go 6-10mg), a world apart from the daily 2-5mg used to prevent transplant rejection. The long ~63h half-life is why weekly dosing still sustains mTORC1 inhibition for days while allowing mTOR to recover between doses (the intended "pulse" that spares mTORC2 and lets protein synthesis/immune surveillance resume). Absorption is affected by food and grapefruit (a CYP3A4/P-gp interaction). Keep timing consistent. This is a prescription drug: dosing, and especially any use alongside other immunosuppressants, should be physician-supervised with periodic bloodwork.
The long half-life is one reason weekly dosing sustains meaningful mTORC1 inhibition between doses.
Side Effects
Immunosuppression / Infection Risk
uncommonThe defining risk. At high/daily doses it suppresses immune function; at low weekly longevity doses this is much less pronounced (and may even reverse), but the risk is not zero.
Use the lowest effective weekly dose; consider pausing around illness, vaccination timing, or surgery; physician oversight and periodic labs.
Mouth Ulcers / Aphthous Stomatitis
commonCanker-sore-like mouth ulcers are the most frequently reported side effect at longevity doses.
Usually dose-related; reduce dose or spacing. Often resolves with a lower dose.
Glucose Intolerance / Insulin Resistance
uncommonChronic/frequent dosing can impair glucose tolerance and lipids (linked to mTORC2 inhibition). Intermittent weekly dosing is intended to reduce this, and animal data show it is milder than with frequent dosing, but it does not fully eliminate it.
Keep dosing intermittent (weekly), monitor fasting glucose/HbA1c and lipids; some pair with metformin/berberine and diet.
Dyslipidemia
uncommonRaised triglycerides/cholesterol reported mainly with daily immunosuppressive dosing.
Monitor lipids; intermittent dosing reduces incidence.
Impaired Wound Healing
uncommonmTOR inhibition can slow tissue repair, relevant around surgery or injury.
Pause before/after surgery; discuss with a physician.
General Mitigation Strategies
The single biggest lever is schedule: intermittent (weekly) low dosing is designed to capture mTORC1 inhibition/autophagy while avoiding the immunosuppression, glucose intolerance, and lipid effects of daily immunosuppressive dosing. Use the lowest effective dose, monitor glucose/lipids/blood counts, be cautious around infection, vaccination, and surgery, and keep it physician-supervised. Watch the grapefruit/CYP3A4 interaction.
Post Cycle Therapy (PCT)
Not hormonal. No PCT required.
How It Works
Rapamycin binds the intracellular protein FKBP12; the complex inhibits mTORC1 (mechanistic target of rapamycin complex 1). mTORC1 normally senses nutrients/amino acids and growth-factor signalling and drives protein synthesis, cell growth, and ribosome biogenesis while suppressing autophagy. Inhibiting it engages autophagy (cellular "self-cleaning"/recycling) and shifts cells toward a maintenance/repair state, the leading candidate mechanism for its lifespan extension. Acute/intermittent dosing is relatively selective for mTORC1; chronic daily dosing also inhibits mTORC2, which is thought to drive the glucose-intolerance and lipid effects seen at immunosuppressive dosing.
Fundamentals
Reference on the practices relevant to Rapamycin (Sirolimus): how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
FDA-approved as Rapamune for organ-transplant rejection; longevity use is off-label.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Rapamycin (sirolimus) is not listed on the WADA Prohibited List. It is an mTOR inhibitor with no anabolic or performance-enhancing action (it can be mildly anti-anabolic), so it does not fall under S1 or the peptide/hormone classes. It is nonetheless a prescription immunosuppressant, a therapeutic-use context, not a doping one. Athletes should always verify current status via GlobalDRO, as list wording can change.
References
- Rapamycin does not compromise hypertrophy or physical performance after PoWeR; intermittent dosing partially spares glucose disruption (mouse, 2025 bioRxiv preprint, PMC11952434)
- RAPA-EX-01 trial protocol: once-weekly sirolimus + home exercise in older adults
- RAPA-EX-01 results: sirolimus did not enhance (and may have attenuated) functional gains from exercise, J Cachexia Sarcopenia Muscle 2026 (PMID 41985884)
- PEARL trial: safety & healthspan of low-dose rapamycin at 1 year, Aging (Albany NY) 2025 (PMC12074816)